ToolGen
ToolGen, a biotechnology company, focuses on the development of genome editing technology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | $53.8m | IPO | |
| Total Funding | 000k | ||
| KRW | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (53 %) | 48 % | (19 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1238 %) | (2296 %) | (1208 %) | (1955 %) |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1295 %) | (2445 %) | (3837 %) | 699 % |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 341 % | 847 % | 612 % | 768 % |
Source: Company filings or news article
Related Content
ToolGen is a leading biotechnology company specializing in gene editing technologies, particularly using the CRISPR Cas9 system. The company operates in the biotechnology and life sciences market, focusing on both therapeutic applications and agricultural improvements. ToolGen serves a diverse range of clients, including pharmaceutical companies, agricultural firms, and research institutions. The business model revolves around licensing its foundational patents and proprietary technologies to other companies, thereby generating revenue through licensing fees and royalties. ToolGen's innovations aim to enhance crop traits and develop new therapies, addressing critical issues like food shortages and disease treatment. The company has established partnerships with major industry players such as Thermo Fisher Scientific, Monsanto, and Bayer, further solidifying its position in the market.
Keywords: CRISPR, gene editing, biotechnology, therapeutics, agriculture, licensing, patents, eukaryotic cells, crop traits, disease treatment.